Abstract:Glioblastoma (GBM) is a highly malignant type of brain tumor with limited treatment options. Recent research has focused on epigenetic regulatory factors, such as Enhancer of Zeste Homolog 2 (EZH2), which plays a role in gene expression through epigenetic modifications. EZH2 inhibitors have been developed as potential therapeutic agents for GBM, but resistance to these inhibitors remains a considerable challenge. This study aimed to investigate the role of ribosomal S6 protein kinase 4 (RSK4) in GBM and its association with resistance to EZH2 inhibitors. We first induced drug resistance in primary GBM cell lines by treatment with an EZH2 inhibitor and observed increases in the expression of stemness markers associated with glioblastoma stem cells (GSCs) in the drug-resistant cells. We also found high expression of RSK4 in GBM patient samples and identified the correlation of high RSK4 expression with poor prognosis and GSC marker expression. Further experiments showed that knocking down RSK4 in drug-resistant GBM cells restored their sensitivity to EZH2 inhibitors and decreased the expression of GSC markers, thus reducing their self-renewal capacity. From a mechanistic perspective, we discovered that RSK4 directly phosphorylates EZH2, activating the EZH2/STAT3 pathway and promoting resistance to EZH2 inhibitors in GBM. We also found that combining EZH2 inhibitors with an RSK4 inhibitor called BI-D1870 had better inhibitory effects on GBM occurrence and progression in both in vitro and in vivo experiments. In conclusion, this study demonstrates that RSK4 enhances cancer stemness and mediates resistance to EZH2 inhibitors in GBM. Combination treatment with EZH2 inhibitors and RSK4 inhibitors is a promising potential therapeutic strategy for GBM. Collectively, our results strongly demonstrate that RSK4 regulates the EZH2/STAT3 pathway to promote GSC maintenance and EZH2i resistance in a PRC2-independent manner, indicating that RSK4 is a promising therapeutic target for GBM.

Ubiquitin-specific protease 4 promotes glioblastoma multiforme via activating ERK pathway

Identification of Ubiquitin-Specific Protease 32 As an Oncogene in Glioblastoma and the Underlying Mechanisms

USP7 inhibition induces apoptosis in glioblastoma by enhancing ubiquitination of ARF4

USP5 Sustains the Proliferation of Glioblastoma Through Stabilization of CyclinD1

OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway

USP7 Inhibition Induces Apoptosis in Glioblastoma by Stabilizing ARF4

Transcriptome Analysis and Single-Cell Sequencing Analysis Constructed the Ubiquitination-Related Signature in Glioma and Identified USP4 as a Novel Biomarker

Overexpression of Ubiquitin Specific Proteases 44 Promotes the Malignancy of Glioma by Stabilizing Tumor-Promoter Securin.

Pharmacological inhibition of the ubiquitin-specific protease 8 effectively suppresses glioblastoma cell growth

Loss of Deubiquitylase USP2 Triggers Development of Glioblastoma Via TGF-β Signaling.

ANGPTL4 Induces TMZ Resistance of Glioblastoma by Promoting Cancer Stemness Enrichment via the EGFR/AKT/4E-BP1 Cascade

Stabilization of KPNB1 by deubiquitinase USP7 promotes glioblastoma progression through the YBX1-NLGN3 axis

Ribosomal S6 protein kinase 4 promotes resistance to EZH2 inhibitors in glioblastoma

USP9X deubiquitinates TRRAP to promote glioblastoma cell proliferation and migration and M2 macrophage polarization

UBE2S facilitates glioblastoma progression through activation of the NF-κB pathway via attenuating K11-linked ubiquitination of AKIP1

UBE2D3 Activates SHP-2 Ubiquitination to Promote Glycolysis and Proliferation of Glioma via Regulating STAT3 Signaling Pathway

Ubiquitin-specific Protease 2a Stabilizes MDM4 and Facilitates the P53-Mediated Intrinsic Apoptotic Pathway in Glioblastoma.

UBE2T Promotes Glioblastoma Malignancy Through Ubiquitination‐mediated Degradation of RPL6

Bulk and Single Cells Transcriptomes with Experimental Validation Identify USP18 As a Novel Glioma Prognosis and Proliferation Indicator

Deubiquitinase PSMD14 promotes tumorigenicity of glioblastoma by deubiquitinating and stabilizing β‐catenin

Suppression of the USP10/CCND1 Axis Induces Glioblastoma Cell Apoptosis